Cytokinetics, Incorporated
Stock Details
Is it expensive?
Trailing P/E Ratio
-10.93
Forward P/E Ratio
-15.21
PEG Ratio
-0.48
-15.29
Price-to-Sales (TTM)
92.75
-10.66
-6.65
Market Cap
9.70B
9.62B
Is it profitable?
Net Profit Margin (TTM)
-372.55%
Gross Profit Margin
86.81%
Diluted EPS (TTM)
-6.85
119.00%
105.82M
Is it growing?
1,125.80%
1,125.78%
Is it risky?
0.38
-1.75
4.21
1.44B
Who owns it?
118.98%
0.71%
18.75%
124.24M
123.86M
Does it pay?
0.00%
0.00%
--
--
How much cash?
818.55M
-523.85M
-381.06M
6.58
- Price
- 71.48
- Percent Change
- -0.81 (1.12%)
- Previous Close
- 72.29
- Open
- 72.20
- Low
- 70.60
- High
- 73.34
52-Week Range Position (52WRP)
Expensive
Expensive
within its 1-year price range
$71.48
From 52W Low
+126.78%
From 52W High
-10.87%
Today
-1.12%
1Y Change
+121.30%
6M
$64.13
3M
$60.41
1M
$74.84
Today
$71.48
From 52W Low
+126.78%
From 52W High
-10.87%
Today
-1.12%
1Y Change
+121.30%
6M
$64.13
3M
$60.41
1M
$74.84
Today
$71.48
Expensive
within its 1-year price range
$71.48
Multi-Timeframe Analysis (MTA)
Pullback
A brief dip inside a longer uptrend. Pullbacks are normal and healthy. They often represent buying opportunities when the broader multi-period trend remains intact. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-4.5%
3M
+18.3%
6M
+11.5%
1Y
+121.3%
Rate of Change (ROC)
Decelerating
Price has reversed, now falling vs its usual uptrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Cytokinetics, Incorporated
- Founded
- 1997
- CEO
- Robert I. Blum
- Employees
- 498
- Fiscal Year End
- Dec 31, 2024
- Address
350 Oyster Point Boulevard
South San Francisco
California
94080
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.cytokinetics.com
Indicators
Operating Cash Flow
-523.85M
Net Income
-829.61M
Mixed Signal
0.63
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-523.85M
Net Income
-829.61M
Mixed Signal
0.63
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-10.93
Forward P/E Ratio
-15.21
PEG Ratio
-0.48
-15.29
Price-to-Sales (TTM)
92.75
-10.66
-6.65
Market Cap
9.70B
9.62B
Is it profitable?
Net Profit Margin (TTM)
-372.55%
Gross Profit Margin
86.81%
Diluted EPS (TTM)
-6.85
119.00%
105.82M
Is it growing?
1,125.80%
1,125.78%
Is it risky?
0.38
-1.75
4.21
1.44B
Who owns it?
118.98%
0.71%
18.75%
124.24M
123.86M
Does it pay?
0.00%
0.00%
--
--
How much cash?
818.55M
-523.85M
-381.06M
6.58
- Price
- 71.48
- Percent Change
- -0.81 (1.12%)
- Previous Close
- 72.29
- Open
- 72.20
- Low
- 70.60
- High
- 73.34
52-Week Range Position (52WRP)
Expensive
Expensive
within its 1-year price range
$71.48
From 52W Low
+126.78%
From 52W High
-10.87%
Today
-1.12%
1Y Change
+121.30%
6M
$64.13
3M
$60.41
1M
$74.84
Today
$71.48
From 52W Low
+126.78%
From 52W High
-10.87%
Today
-1.12%
1Y Change
+121.30%
6M
$64.13
3M
$60.41
1M
$74.84
Today
$71.48
Expensive
within its 1-year price range
$71.48
Multi-Timeframe Analysis (MTA)
Pullback
A brief dip inside a longer uptrend. Pullbacks are normal and healthy. They often represent buying opportunities when the broader multi-period trend remains intact. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-4.5%
3M
+18.3%
6M
+11.5%
1Y
+121.3%
Rate of Change (ROC)
Decelerating
Price has reversed, now falling vs its usual uptrend. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Cytokinetics, Incorporated
- Founded
- 1997
- CEO
- Robert I. Blum
- Employees
- 498
- Fiscal Year End
- Dec 31, 2024
- Address
350 Oyster Point Boulevard
South San Francisco
California
94080
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.cytokinetics.com